Eupraxia Pharmaceuticals Inc. (TSX: EPRX)
EPRX trades on the Toronto Stock Exchange in Life Sciences, headquartered in British Columbia. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Close · October 14, 2026
C$9.36
-2.40% on the day
Market cap (C$)
C$844.6M
TMX list, September 30, 2026
Market cap (US$)
US$592.2M
Small cap at 1.4263 C$/US$
1-year return
+11.4%
-9.3% year to date
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of September 30, 2026. US$ figures convert C$ at 1.4263 C$ per US$, the Bank of Canada daily rate for October 14, 2026. Close and returns: Yahoo Finance daily closes for EPRX.TO, last bar 2026-10-14, computed by Sophia Capital.
Profile
| Field | Value |
|---|---|
| Ticker | EPRX on the Toronto Stock Exchange |
| Yahoo symbol | EPRX.TO |
| Sector | Life Sciences |
| Headquarters | British Columbia |
| Listed | 2021-03-09 |
| Listing type | IPO |
| Shares outstanding | 65,018,972 |
| Also listed on | NasdaqCM |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0001581178 |
| Website | No company website on record |
| US listing | EPRX |
Returns
| Window | Return |
|---|---|
| 1 day | -2.4% |
| 1 week | -15.0% |
| 1 month | -16.5% |
| 3 months | +5.1% |
| 6 months | -6.5% |
| Year to date | -9.3% |
| 1 year | +11.4% |
| From 52-week high | -27.9% |
| 52-week range | C$7.50 to C$12.99 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
127 documents in 13 types. Each title links to the document at its source.
Annual financial statements (2)
| Document | Type | Filed |
|---|---|---|
| FINANCIAL STATEMENTS Period 2025-12-31 | Annual financial statements (40-F) | 2026-03-13 |
| FINANCIAL STATEMENTS Period 2024-12-31 | Annual financial statements (40-F) | 2025-03-20 |
Interim financial statements (6)
| Document | Type | Filed |
|---|---|---|
| Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2026. Period 2026-06-30 | Interim financial statements (6-K) | 2026-08-11 |
| Consolidated Financial Statements for the three and nine months ended March 31, 2026. Period 2026-03-31 | Interim financial statements (6-K) | 2026-05-12 |
| Consolidated Financial Statements for the three and nine months ended September 30, 2025. Period 2025-09-30 | Interim financial statements (6-K) | 2025-11-04 |
| Consolidated Financial Statements for the three and six months ended June 30, 2025. Period 2025-06-30 | Interim financial statements (6-K) | 2025-08-13 |
MD&A (5)
| Document | Type | Filed |
|---|---|---|
| MANAGEMENT'S DISCUSSION & ANALYSIS Period 2025-12-31 | MD&A (annual) (40-F) | 2026-03-13 |
| MANAGEMENT'S DISCUSSION & ANALYSIS Period 2024-12-31 | MD&A (annual) (40-F) | 2025-03-20 |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and six months ended June 30, 2026. Period 2026-06-30 | MD&A (interim) (6-K) | 2026-08-11 |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three months ended March 31, 2026. Period 2026-03-31 | MD&A (interim) (6-K) | 2026-05-12 |
Annual information form (5)
| Document | Type | Filed |
|---|---|---|
| ANNUAL INFORMATION FORM Period 2025-12-31 | Annual information form (40-F) | 2026-03-13 |
| Managements Discussion and Analysis of Financial Condition and Results of Operations for the three and six months ended June 30, 2025. Period 2025-06-30 | Annual information form (6-K) | 2025-08-13 |
| Managements Discussion and Analysis of Financial Condition and Results of Operations for the three months ended March 31, 2025. Period 2025-03-31 | Annual information form (6-K) | 2025-05-06 |
| ANNUAL INFORMATION FORM Period 2024-12-31 | Annual information form (40-F) | 2025-03-20 |
Material change report (4)
| Document | Type | Filed |
|---|---|---|
| Material Change Report | Material change report (6-K) | 2026-07-15 |
| Material Change Report, dated February 23, 2026 | Material change report (6-K) | 2026-03-06 |
| Material Change Report, dated September 25, 2025 | Material change report (6-K) | 2025-09-29 |
| Material Change Report of the Registrant, dated February 20, 2025 | Material change report (6-K) | 2025-09-19 |
News release (49)
| Document | Type | Filed |
|---|---|---|
| PRESS RELEASE | News release (6-K) | 2026-10-09 |
| PRESS RELEASE | News release (6-K) | 2026-09-30 |
| PRESS RELEASE | News release (6-K) | 2026-09-08 |
| PRESS RELEASE | News release (6-K) | 2026-08-13 |
Management information circular / proxy (7)
| Document | Type | Filed |
|---|---|---|
| Management Information Circular | Management information circular (6-K) | 2026-05-29 |
| Management Information Circular | Management information circular (6-K) | 2025-06-02 |
| Notice of Annual General Meeting of Shareholders | Notice of meeting (6-K) | 2026-05-29 |
| Notice of Record and Meeting Date | Notice of meeting (6-K) | 2026-04-15 |
Report of voting results (2)
| Document | Type | Filed |
|---|---|---|
| Report of Voting Results | Report of voting results (6-K) | 2026-06-22 |
| Report of Voting Results | Report of voting results (6-K) | 2025-06-03 |
Prospectus (7)
| Document | Type | Filed |
|---|---|---|
| F-10/A | Prospectus (short form) (F-10/A) | 2026-08-19 |
| F-10 | Prospectus (short form) (F-10) | 2026-08-06 |
| SUPPL | Prospectus supplement (SUPPL) | 2026-09-02 |
| SUPPL | Prospectus supplement (SUPPL) | 2026-02-20 |
Annual report (2)
| Document | Type | Filed |
|---|---|---|
| 40-F Period 2025-12-31 | Annual report (40-F) (40-F) | 2026-03-13 |
| 40-F Period 2024-12-31 | Annual report (40-F) (40-F) | 2025-03-20 |
Early warning / ownership (10)
| Document | Type | Filed |
|---|---|---|
| Schedule 13D amendment | Schedule 13D (SCHEDULE 13D/A) | 2026-03-16 |
| Schedule 13D amendment | Schedule 13D (SCHEDULE 13D/A) | 2025-09-26 |
| Schedule 13D | Schedule 13D (SC 13D) | 2024-11-07 |
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2026-08-13 |
Certification (20)
| Document | Type | Filed |
|---|---|---|
| Form 52-109F2 Certification of Interim Filings by CEO. | Certification (52-109F2) (6-K) | 2026-08-11 |
| Form 52-109F2 Certification of Interim Filings by CFO. | Certification (52-109F2) (6-K) | 2026-08-11 |
| Form 52-109F2 Certification of Interim Filings by CEO. | Certification (52-109F2) (6-K) | 2026-05-12 |
| Form 52-109F2 Certification of Interim Filings by CFO. | Certification (52-109F2) (6-K) | 2026-05-12 |
Other (8)
| Document | Type | Filed |
|---|---|---|
| EX-5.1 | Consent (F-10/A) | 2026-08-19 |
| EX-5.1 | Consent (F-10) | 2026-08-06 |
| CONSENT OF KPMG LLP Period 2025-12-31 | Consent (40-F) | 2026-03-13 |
| CONSENT OF KPMG LLP Period 2024-12-31 | Consent (40-F) | 2025-03-20 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
Halted: no resumption notice since 2026-04-20 in our data.
| Notice | Action | Reason | Notice |
|---|---|---|---|
| 2026-04-20 12:00 PM ET | Halt | Pending Delisting | CIRO notice |
| 2026-03-09 12:00 PM ET | Halt | Pending Delisting | CIRO notice |
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2024-11-08 | Equity | US$1.9M | US$1.9M | SEC EDGAR |
| 2023-08-22 | Equity | US$128K | US$128K | SEC EDGAR |
| 2016-04-18 | Equity | US$38K | US$38K | SEC EDGAR |
| 2013-09-16 | Equity | US$24K | US$24K | SEC EDGAR |
| 2013-07-11 | Equity | US$10K | US$10K | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| DHT | DRI Healthcare Trust | TSX | C$1.0B | +6.3% | +25.0% |
| GUD | Knight Therapeutics Inc. | TSX | C$1.0B | +5.9% | +83.9% |
| WELL | WELL Health Technologies Corp. | TSX | C$1.2B | -3.3% | -20.2% |
| FRX | Fennec Pharmaceuticals Inc. | TSX | C$542.2M | -15.4% | +17.6% |
| WEED | Canopy Growth Corporation | TSX | C$537.4M | -22.0% | -46.4% |
The app has the price chart, every filing, private raises and the full peer set for EPRX.
Open in the app